{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T04:53:26Z","timestamp":1777870406045,"version":"3.51.4"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2018,6,7]],"date-time":"2018-06-07T00:00:00Z","timestamp":1528329600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s40620-018-0501-7","type":"journal-article","created":{"date-parts":[[2018,6,6]],"date-time":"2018-06-06T23:17:17Z","timestamp":1528327037000},"page":"751-756","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Safety and effectiveness of rivaroxaban and warfarin in moderate-to-advanced CKD: real world data"],"prefix":"10.1093","volume":"31","author":[{"given":"Luca","family":"Di Lullo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Tripepi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Ronco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"De Pascalis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Barbera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Granata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biagio Raffaele","family":"Di Iorio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernesto","family":"Paoletti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maura","family":"Ravera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Fusaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Bellasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,6,7]]},"reference":[{"key":"501_CR1","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.thromres.2017.04.027","volume":"155","author":"L Lullo Di","year":"2017","unstructured":"Di Lullo L, Ronco C, Cozzolino M et al (2017) Nonvitamin K-dependent oral anticoagulants (NOACs) in chronic kidney disease patients with atrial fibrillation. Thromb Res 155:38\u201347","journal-title":"Thromb Res"},{"key":"501_CR2","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.1016\/j.jacc.2016.02.082","volume":"67","author":"KE Chan","year":"2016","unstructured":"Chan KE, Giugliano RP, Patel MR et al (2016) Nonvitamin K anticoagulant agents in patients with advanced chronic kidney disease or on dialysis with AF. J Am Coll Cardiol 67:2888\u20132899","journal-title":"J Am Coll Cardiol"},{"key":"501_CR3","unstructured":"Bellasi A, Di Lullo L, Melfa G et al. New oral anticoagulants (NOAC) in nephrology. G Ital Nefrol 2016; 33"},{"key":"501_CR4","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1093\/europace\/eux240","volume":"19","author":"GYH Lip","year":"2017","unstructured":"Lip GYH, Collet JP, Caterina R et al (2017) Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLEACE). Europace 19:1757\u20131758","journal-title":"Europace"},{"key":"501_CR5","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1093\/europace\/euq160","volume":"12","author":"AJ Camm","year":"2010","unstructured":"Camm AJ, Kirchhof P, Lip GY et al (2010) Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 12:1360\u20131420","journal-title":"Europace"},{"key":"501_CR6","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1159\/000481207","volume":"46","author":"MC Lin","year":"2017","unstructured":"Lin MC, Streja E, Soohoo M et al (2017) Warfarin use and increased mortality in end-stage renal disease. Am J Nephrol 46:249\u2013256","journal-title":"Am J Nephrol"},{"key":"501_CR7","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1093\/ndt\/gfx199","volume":"33","author":"PWM Voskamp","year":"2018","unstructured":"Voskamp PWM, Rookmaaker MB, Verhaar MC et al (2018) Vitamin K antagonist use and mortality in dialysis patients. Nephrol Dial Transplant 33:170\u2013176","journal-title":"Nephrol Dial Transplant"},{"key":"501_CR8","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1160\/TH-17-10-0709","volume":"117","author":"GYH Lip","year":"2017","unstructured":"Lip GYH, Collet JP, de Caterina R et al. (2017) Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: executive summary of a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, Endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLEACE). Thromb Haemost 117:2215\u20132236","journal-title":"Thromb Haemost"},{"key":"501_CR9","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euy039","author":"H Heidbuchel","year":"2018","unstructured":"Heidbuchel H, Dagres N, Antz M, Kuck KH, Lazure P, Murray S, Carrera C, Hindricks G, Vahanian A (2018) European Society of Cardiology (ESC) and European Heart Rhythm Association (EHRA). Europace. \n                    https:\/\/doi.org\/10.1093\/europace\/euy039","journal-title":"Europace"},{"key":"501_CR10","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1053\/j.ajkd.2017.08.003","volume":"70","author":"VK Bansal","year":"2017","unstructured":"Bansal VK, Herzog CA, Sarnak MJ et al (2017) Oral anticoagulants to prevent stroke in nonvalvular atrial fibrillation in Patients with CKD Stage 5D: an NKF-KDOQI controversies report. Am J Kidney Dis 70:859\u2013868","journal-title":"Am J Kidney Dis"},{"key":"501_CR11","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s40620-016-0374-6","volume":"30","author":"J Tan","year":"2017","unstructured":"Tan J, Bae S, Segal JB et al (2017) Treatment of atrial fibrillation with warfarin among older adults with end stage renal disease. J Nephrol 30:831\u2013839","journal-title":"J Nephrol"},{"key":"501_CR12","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s40620-016-0364-8","volume":"30","author":"S Genovesi","year":"2017","unstructured":"Genovesi S, Rebora P, Gallieni M et al (2017) Effect of oral anticoagulant therapy on mortality in end-stage renal disease patients with atrial fibrillation: a prospective study. J Nephrol 30:573\u2013581","journal-title":"J Nephrol"},{"key":"501_CR13","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.ahj.2015.07.006","volume":"170","author":"S Bansilal","year":"2015","unstructured":"Bansilal S, Bloomgarden Z, Halperin JL et al (2015) Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the rivaroxaban once-daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF trial). Am Heart J 170:675\u2013682 e678","journal-title":"Am Heart J"},{"key":"501_CR14","doi-asserted-by":"publisher","first-page":"3451","DOI":"10.1038\/s41598-018-21884-y","volume":"8","author":"HY Huang","year":"2018","unstructured":"Huang HY, Lin SY, Cheng SH et al (2018) Effectiveness and safety of different rivaroxaban dosage regimens in patients with non-valvular atrial fibrillation: a nationwide, population-based cohort study. Sci Rep 8:3451","journal-title":"Sci Rep"},{"key":"501_CR15","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ijcard.2016.04.170","volume":"217","author":"L Lullo Di","year":"2016","unstructured":"Di Lullo L, Rivera R, Barbera V et al (2016) Sudden cardiac death and chronic kidney disease: from pathophysiology to treatment strategies. Int J Cardiol 217:16\u201327","journal-title":"Int J Cardiol"},{"key":"501_CR16","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.2215\/CJN.01860217","volume":"12","author":"N Bansal","year":"2017","unstructured":"Bansal N, Zelnick LR, Alonso A et al (2017) eGFR and Albuminuria in relation to risk of incident atrial fibrillation: a meta-analysis of the jackson heart study, the multi-ethnic study of atherosclerosis, and the cardiovascular health study. Clin J Am Soc Nephrol 12:1386\u20131398","journal-title":"Clin J Am Soc Nephrol"},{"key":"501_CR17","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s40620-017-0413-y","volume":"31","author":"A Losito","year":"2018","unstructured":"Losito A, Nunzi E, Pittavini L et al (2018) Cardiovascular morbidity and long term mortality associated with in hospital small increases of serum creatinine. J Nephrol 31:71\u201377","journal-title":"J Nephrol"},{"key":"501_CR18","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s40620-015-0244-7","volume":"30","author":"A Losito","year":"2017","unstructured":"Losito A, Zampi I, Pittavini L et al (2017) Association of reduced kidney function with cardiovascular disease and mortality in elderly patients: comparison between the new Berlin initiative study (BIS1) and the MDRD study equations. J Nephrol 30:81\u201386","journal-title":"J Nephrol"},{"key":"501_CR19","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s40620-015-0239-4","volume":"29","author":"D Gibertoni","year":"2016","unstructured":"Gibertoni D, Mandreoli M, Rucci P et al (2016) Excess mortality attributable to chronic kidney disease. Results from the PIRP project. J Nephrol 29:663\u2013671","journal-title":"J Nephrol"},{"key":"501_CR20","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1105594","volume":"367","author":"JB Olesen","year":"2012","unstructured":"Olesen JB, Lip GY, Kamper AL et al (2012) Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 367:625\u2013635","journal-title":"N Engl J Med"},{"key":"501_CR21","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1161\/CIRCULATIONAHA.111.084996","volume":"125","author":"D Capodanno","year":"2012","unstructured":"Capodanno D, Angiolillo DJ (2012) Antithrombotic therapy in patients with chronic kidney disease. Circulation 125:2649\u20132661","journal-title":"Circulation"},{"key":"501_CR22","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1093\/eurheartj\/ehv466","volume":"37","author":"AJ Camm","year":"2016","unstructured":"Camm AJ, Amarenco P, Haas S et al (2016) XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J 37:1145\u20131153","journal-title":"Eur Heart J"},{"key":"501_CR23","doi-asserted-by":"crossref","unstructured":"Martinez BK, Sood NA, Bunz TJ et al. Effectiveness and safety of apixaban, dabigatran, and rivaroxaban versus warfarin in frail patients with nonvalvular atrial fibrillation. J Am Heart Assoc 2018; 7","DOI":"10.1161\/JAHA.118.008643"},{"key":"501_CR24","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2147\/VHRM.S134394","volume":"14","author":"K Vimalesvaran","year":"2018","unstructured":"Vimalesvaran K, Dockrill SJ, Gorog DA (2018) Role of rivaroxaban in the management of atrial fibrillation: insights from clinical practice. Vasc Health Risk Manag 14:13\u201321","journal-title":"Vasc Health Risk Manag"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40620-018-0501-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-018-0501-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-018-0501-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:57:40Z","timestamp":1777564660000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/31\/5\/751\/8371449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,7]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["501"],"URL":"https:\/\/doi.org\/10.1007\/s40620-018-0501-7","relation":{},"ISSN":["1121-8428","1724-6059"],"issn-type":[{"value":"1121-8428","type":"print"},{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,7]]},"assertion":[{"value":"28 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}